金吾财讯 | 黑石集团(BX)旗下黑石生命科学公司和Anthos治疗公司宣布诺华制药(NVS)将以31亿美元收购Anthos，交易预计将于2025年上半年完成。Anthos股东将获得9.25亿美元的首付款。
对于诺华而言，此次收购是其在心血管领域的重要布局。诺华在心血管领域根基深厚，而阿贝拉西单抗的加入有望进一步丰富其产品线，为全球数百万面临中风高风险的心房颤动患者提供更有效的治疗选择。
Anthos 首席执行官 Bill Meury 表示：“诺华在心血管领域的深厚底蕴，使其在推进阿贝拉西单抗的临床开发以及将这一创新产品带给医疗服务提供者和患者方面，具有得天独厚的优势。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.